Renaissance Technologies
AMRX icon

Renaissance Technologies’s Amneal Pharmaceuticals AMRX Stock Holding History

Renaissance Technologies’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
87,487
-189,150
-68% -$2.59M ﹤0.01% 2116
2026
Q1 		$3.44M Buy
276,637
+260,237
+1,587% +$3.49M 0.01% 1582
2025
Q4 		$207K Sell
16,400
-73,500
-82% -$841K ﹤0.01% 2876
2025
Q3 		$900K Sell
89,900
-338,100
-79% -$3.03M ﹤0.01% 2539
2025
Q2 		$3.46M Sell
428,000
-196,700
-31% -$1.48M ﹤0.01% 1756
2025
Q1 		$5.23M Sell
624,700
-61,800
-9% -$516K 0.01% 1405
2024
Q4 		$5.44M Sell
686,500
-69,100
-9% -$580K 0.01% 1403
2024
Q3 		$6.29M Buy
755,600
+72,900
+11% +$570K 0.01% 1300
2024
Q2 		$4.34M Buy
682,700
+149,970
+28% +$952K 0.01% 1402
2024
Q1 		$3.23M Buy
532,730
+324,930
+156% +$1.83M 0.01% 1718
2023
Q4 		$1.26M Buy
207,800
+93,700
+82% +$417K ﹤0.01% 2249
2023
Q3 		$482K Buy
+114,100
New +$426K ﹤0.01% 2717
2023
Q1 		– Sell
-76,400
Closed -$152K – 3946
2022
Q4 		$152K Sell
76,400
-65,500
-46% -$147K ﹤0.01% 3500
2022
Q3 		$287K Sell
141,900
-30,500
-18% -$85.5K ﹤0.01% 3229
2022
Q2 		$548K Buy
172,400
+103,800
+151% +$376K ﹤0.01% 3110
2022
Q1 		$286K Buy
+68,600
New +$304K ﹤0.01% 3487
2021
Q2 		– Sell
-448,660
Closed -$3.02M – 3428
2021
Q1 		$3.02M Buy
448,660
+276,111
+160% +$1.53M ﹤0.01% 1962
2020
Q4 		$789K Buy
+172,549
New +$765K ﹤0.01% 2620
2019
Q3 		– Sell
-71,700
Closed -$514K – 3409
2019
Q2 		$514K Sell
71,700
-315,700
-81% -$3.23M ﹤0.01% 2983
2019
Q1 		$5.49M Sell
387,400
-566,300
-59% -$7.48M 0.01% 1748
2018
Q4 		$12.9M Buy
953,700
+573,000
+151% +$10.3M 0.01% 1160
2018
Q3 		$8.45M Buy
+380,700
New +$8.01M 0.01% 1463

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Renaissance Technologies's AMRX Position: Q2 2026 in Review

Renaissance Technologies reduced its Amneal Pharmaceuticals (AMRX) stake by 68% in Q2 2026, selling an estimated $2.59M and leaving 87,487 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Renaissance Technologies first reported a position in AMRX in Q3 2018 and has held it in 22 quarters since. The position peaked at $12.9M in Q4 2018. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Renaissance Technologies held 87,487 shares of Amneal Pharmaceuticals worth $1.51M as of Q2 2026.
  • Renaissance Technologies sold 189,150 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2116 holding.
  • Renaissance Technologies first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 22 quarters since.
  • Renaissance Technologies's Amneal Pharmaceuticals position peaked at $12.9M in Q4 2018.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.